Role of β3-Adrenergic Receptor in Bone Marrow Transplant as Therapeutical Support in Cancer.
bone marrow
bone marrow transplant (BMT)
cancer
hematopoietic stem cell (HSC)
β3-adrenoreceptor
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2022
2022
Historique:
received:
04
03
2022
accepted:
09
05
2022
entrez:
27
6
2022
pubmed:
28
6
2022
medline:
28
6
2022
Statut:
epublish
Résumé
β3-adrenergic receptor (β3-AR) is the last β-adrenoceptor subtype identified. β3-AR is widely expressed and regulates numerous physiological processes, and it is also a potential target for the treatment of many diseases, including cancers. For some types of cancers, bone marrow transplant (BMT) represents a valid therapeutic support, especially in the case of the necessity of high-dose chemotherapy and radiotherapy. For a successful BMT, it is necessary that a donor's hematopoietic stem cells (HSCs) correctly reach the staminal niche in the recipient's bone marrow (BM) and contribute to restore normal hematopoiesis in order to rapidly repopulate BM and provide all the healthy blood cells of which the patient needs. Generally, it takes a long time. Control and accelerate homing and engraftment of HSCs could represent a helpful approach to avoid the complications and undesirable effects of BMT. The evidence that the β-adrenergic system has a role in the BM can be found in different studies, and this leads us to hypothesize that studying this field could be interesting to meliorate the most critical aspects of a BMT. Here, we collected the data present in literature about the role of β3-AR in the BM with the purpose of discovering a possible utility of β3-AR modulation in regulating HSC trafficking and hematopoiesis.
Identifiants
pubmed: 35756654
doi: 10.3389/fonc.2022.889634
pmc: PMC9213652
doi:
Types de publication
Journal Article
Langues
eng
Pagination
889634Informations de copyright
Copyright © 2022 Nastasi, Bruno, Favre and Calvani.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Naunyn Schmiedebergs Arch Pharmacol. 2004 Feb;369(2):151-9
pubmed: 14730417
Science. 1989 Sep 8;245(4922):1118-21
pubmed: 2570461
J Pediatr Hematol Oncol. 2008 Aug;30(8):575-83
pubmed: 18799933
Semin Cell Dev Biol. 2004 Jun;15(3):281-8
pubmed: 15125891
Int J Obes. 1983;7(5):409-14
pubmed: 6139348
Pharmacol Rev. 2004 Mar;56(1):31-52
pubmed: 15001662
Brain Behav Immun. 2012 May;26(4):635-41
pubmed: 22306453
Pharmacol Res. 2009 Apr;59(4):221-34
pubmed: 19429463
J Immunol. 1985 Aug;135(2 Suppl):755s-765s
pubmed: 2861231
Br J Pharmacol. 2019 Jul;176(14):2539-2558
pubmed: 30809805
Blood. 2019 Jan 17;133(3):224-236
pubmed: 30361261
Br J Pharmacol. 2010 Mar;159(5):1022-38
pubmed: 20132209
N Engl J Med. 1957 Sep 12;257(11):491-6
pubmed: 13464965
Oncotarget. 2017 Jan 24;8(4):6446-6460
pubmed: 28031536
J Clin Lab Anal. 2005;19(2):47-79
pubmed: 15756708
Cell Physiol Biochem. 2018;48(2):847-862
pubmed: 30032151
Expert Opin Ther Targets. 2010 May;14(5):567-75
pubmed: 20350049
Nat Med. 2018 Jun;24(6):782-791
pubmed: 29736022
Blood. 2014 Jul 17;124(3):344-53
pubmed: 24914142
Science. 2002 May 31;296(5573):1636-9
pubmed: 12040175
Cells. 2019 Apr 16;8(4):
pubmed: 30995798
Int J Mol Sci. 2020 Feb 20;21(4):
pubmed: 32093135
Front Immunol. 2020 May 20;11:956
pubmed: 32508835
Oncology. 2008;75(3-4):224-9
pubmed: 18852493
Curr Opin Organ Transplant. 2008 Feb;13(1):53-8
pubmed: 18660707
EXCLI J. 2016 Feb 15;15:134-43
pubmed: 27092040
J Oncol. 2010;2010:539706
pubmed: 20508839
Rom J Morphol Embryol. 2009;50(2):169-79
pubmed: 19434307
Cell Stem Cell. 2018 Oct 4;23(4):572-585.e7
pubmed: 30174297
Int J Mol Sci. 2020 Jun 12;21(12):
pubmed: 32545695
ChemMedChem. 2009 Dec;4(12):2080-97
pubmed: 19882697
Ann N Y Acad Sci. 2010 Mar;1192:139-44
pubmed: 20392229
J Neuroimmune Pharmacol. 2020 Mar;15(1):82-92
pubmed: 30762159
Clin Cancer Res. 2012 Mar 1;18(5):1201-6
pubmed: 22186256
Blood Cells. 1978;4(1-2):7-25
pubmed: 747780
Nature. 1984 May 10-16;309(5964):163-5
pubmed: 6325935
Oncotarget. 2015 Mar 10;6(7):4615-32
pubmed: 25474135
Blood Transfus. 2012 Oct;10(4):542-4
pubmed: 22790268
Mol Pharmacol. 1993 Apr;43(4):548-55
pubmed: 8386307
Cell Signal. 1996 Aug;8(5):355-64
pubmed: 8911684
Mediterr J Hematol Infect Dis. 2017 Apr 19;9(1):e2017032
pubmed: 28512561
J Mol Med (Berl). 2013 Dec;91(12):1407-19
pubmed: 23907236
Oncogene. 2020 Jan;39(2):368-384
pubmed: 31477835
J Cardiovasc Pharmacol. 2016 Mar;67(3):193-202
pubmed: 26751266
Semin Cancer Biol. 2013 Dec;23(6 Pt B):533-42
pubmed: 24012659
Haematologica. 2013 Nov;98(11):1663-6
pubmed: 24186311
Front Immunol. 2016 Sep 16;7:362
pubmed: 27695456
Nature. 2008 Mar 27;452(7186):442-7
pubmed: 18256599
Mod Pathol. 2012 Nov;25(11):1446-51
pubmed: 22743651